Be Aware of Finerenone's Role for Diabetic Kidney Disease
November 2021
Finerenone (Kerendia) will be a new Rx for patients with chronic kidney disease (CKD) due to type 2 diabetes.
It's the first "nonsteroidal mineralocorticoid receptor antagonist"...and is approved to slow CKD progression and improve CV outcomes in these patients.
Finerenone is thought to limit fibrosis and inflammation in the kidneys and heart...by blocking effects of aldosterone.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote